Article
Author(s):
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Findings of a study published online ahead of print in the July 2022 issue of The American Journal of Managed Care® were featured in an article published by Pharmacy Times. The study, “Projected US Savings From Biosimilars, 2021-2025,” indicated that projected savings from biosimilars from 2021 to 2025 were $38.4 billion vs conditions as of quarter 4 of 2020—driven primarily by new biosimilar entry. Savings were noted to be $124.5 billion under an upper-bound scenario. The findings were also covered by News Medical Life Sciences.